MadridModerna and Merck’s vaccine cut melanoma relapse or death 42%.
A Phase 2b study showed 49%, and Moderna shares, up 500% this year, fell.
Each dose is made from the patient’s own tumour and given with Keytruda, versus Keytruda alone, in over 1,100 patients.
Citi questioned whether the benefit justifies individualized tumour harvesting and manufacturing.
The formal presentation comes Saturday at the European Society for Medical Oncology Congress.
How each outlet framed it
drawn from 200+ reports worldwide
- Investing.com
- attributes the selloff to the premature disclosure, not the trial data, and ties the 42% result to Phase 2b's 49%
Sources: Investing.com